Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

The trial is testing epcoritamab, a biological treatment administered subcutaneously, either as a monotherapy or in combination with standard-of-care (SOC) chemotherapy agents. The goal is to ...

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic ...

Epcoritamab is part of a class of drugs called bispecific T-cell engagers. In essence, epcoritamab has 2 binding epitopes, 1 to CD20, which would target malignant or normal B cells, and the other ...

SAN DIEGO — Epcoritamab exhibited encouraging efficacy among heavily pretreated patients with advanced chronic lymphocytic leukemia, according to study results presented at ASH Annual Meeting ...

AbbVie (ABBV) announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with ...

AbbVie (NYSE: ABBV) today announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...

AbbVie says FDA has granted breakthrough therapy designation to epcoritamab for a type of lymphoma By Ciara Linnane Last Updated: Nov. 27, 2023, 10:56 a.m. ET First Published: Nov. 27, 2023, 7:16 ...